N/A Completed N=228 Randomized Quadruple-blind Prevention

Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer

Peptic Ulcer

Source: ClinicalTrials.gov NCT02418312 ↗

Enrolled (actual)

228

Serious AEs

0.0%

Results posted

Mar 2019

Primary outcomePrimary: Number of Participants With Healed Peptic Ulcer — 106; 101 participants

Summary

Whether H2 receptor antagonist can prevent thienopyridine-related peptic ulcer remains unclear.

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants With Healed Peptic Ulcer	106; 101	—

Eligibility Criteria

Inclusion Criteria

The past history of gastroduodenal ulcer and underwent endoscopy for dyspeptic symptoms.
thienopyridine users without baseline gastroduodenal ulcer at initial endoscopy.
They are adult patients aged least 20 years of age.

Exclusion Criteria

They have a history of gastric or duodenal surgery other than oversewing of a perforation.
They require long-term treatment with non-steroidal anti-inflammatory drugs.
serious disease.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02418312). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.